Nebraska Medicine Seeks Acute Myeloid Leukemia Patients for Multi-Center Drug Trial
The University of Nebraska Medical Center (UNMC, net.unmc.edu/ctsearch/study.php?118-20) and Nebraska Medicine are seeking patients suffering from relapsed or refractory acute myeloid leukemia (AML) to partake in a multi-center clinical trial to discover new treatments for the disease. Dr. Vijaya Bhatt, MBBS, an associate professor for and the medical director of the leukemia program in the UNMC Department of Internal Medicine, is leading the study with patients at the Fred & Pamela Buffett Cancer Center. Dr. Bhatt and his team are evaluating whether the drugs—Gemtuzumab and Venetoclax—can kill leukemia stem cells. The phase I study will investigate the maximum safe and tolerated dose for this promising, new combination therapy. The study is open to patients 18-75 years of age who, at the time of recruitment, have had AML relapse or have not responded to treatment. In addition to patients at the Fred & Pamela Buffett Cancer Center and the University of Illinois Health, the study is open to patients at Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the University of Michigan Rogel Cancer Center.
The mission of the University of Nebraska Medical Center (UNMC) and Nebraska Medicine is to lead the world in transforming lives to create a healthy future for all individuals and communities. To learn more about the acute myeloid leukemia study, contact (402) 836-9171 / amberley.proctor@unmc.edu or visit net.unmc.edu/ctsearch/study.php?118-20.